Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
| 대상 질환 | Alzheimer's Disease |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Georgetown University |
| 상태 | 완료 |
| 참여자 수 | 37 명 |
| 중재(약물) | Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth |
| 시작일 | 2017년 1월 |
| 완료일 | 2020년 12월 |
| 결과 공개일 | 2026년 7월 23일 |
요약
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition, and stabilization of CSF total Tau and p-Tau231/181 and Abeta42/40 levels. The investigators hypothesize that Nilotinib will decrease brain load of amyloid using amyloid positron emission tomography (PET). The investigators also predict that Nilotinib will reduce CSF markers of cell death, including neuron specific enolase (NSE) and S100B.
Safety Will be Measured by Number of Participants Experiencing the Occurrence of Adverse Events and/or Abnormal Laboratory Values
| Group 1 (Placebo) | 2 events |
|---|---|
| Group 2 (Treated) | 0 events |
| Group 1 (Placebo) | 1 events |
| Group 2 (Treated) | 1 events |
| Group 1 (Placebo) | 1 events |
| Group 2 (Treated) | 0 events |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
- Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
- Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
- Technology and Family Thriving Study — University of California, Santa Barbara
- Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation